Over the past 30 years, medical advances have contributed to a significant decline of mortality from cardiovascular diseases. However, cardiovascular diseases still account for the largest number of deaths worldwide, with over 17 million annual deaths, representing 30% of all global death. According to WHO, by 2030, the number of people who die from cardiovascular diseases, mainly from heart diseases and strokes, is expected to reach 23.3 million. Among others, our efforts are on the correction of metabolic disorders, including hyperlipidemia. Hyperlipidemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Although hyperlipidemia does not cause symptoms, it can significantly increase your risk of developing cardiovascular disease. Because of these risks, treatment is often recommended for people with hyperlipidemia.

We have developed a nano-formulation of fenofibrate 145mg tablet to address the generic solution to help patients in reducing cholesterol and triglycerides (fatty acids) level in their blood. High levels of these types of fat in the blood are associated with an increased risk of clogged arteries.